AOD-9604 Stacking: Combinations That Users Report Because AOD-9604 targets a single pathway (beta-3 adrenergic lipolysis), many users combine it with peptides that address complementary mechanisms
Adrenaline/Noradrenaline As a common effect including counteraction of the sotalol, class II and class III antiarrhythmic and beta-blocker [52], and counteraction of the isoprenaline, a prototype of beta-agonists [53], occurred counteraction of occlusion/occlusion-like syndromes, peripherally and centrally, and there is a BPC 157 therapy (activation of the collateral pathways, i.e., azygos vein direct flow delivery instantly occurred) [40,41,42,43,47,48,49,50,51,52,53,54,55,56]
Same molecules
Chang, C.-H., Tsai, W.-C., Hsu, Y.-H., & Su Pang, J.-H